Transient Cold Storage Prior to Normothermic Liver Perfusion May Facilitate Adoption of a Novel Technology

Carlo D. L. Ceresa, David Nasralla, Christopher J. E. Watson, Andrew J. Butler, Constantin C. Coussios, Keziah Crick, Leanne Hodson, Charles Imber, Wayel Jassem, Simon R. Knight, Hynek Mergental, Rutger J. Ploeg, Joerg M. Pollok, Alberto Quaglia, A. M. James Shapiro, Annemarie Weissenbacher, Peter J. Friend – 17 June 2019 – Clinical adoption of normothermic machine perfusion (NMP) may be facilitated by simplifying logistics and reducing costs. This can be achieved by cold storage of livers for transportation to recipient centers before commencing NMP.

Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development

Justin D. Schumacher, Bo Kong, Jason Wu, Daniel Rizzolo, Laura E. Armstrong, Monica D. Chow, Michael Goedken, Yi‐Horng Lee, Grace L. Guo – 17 June 2019 – Farnesoid X receptor (FXR) induces fibroblast growth factor 15 (FGF15; human ortholog FGF19) in the gut to potently inhibit bile acid (BA) synthesis in the liver. FXR activation in hepatic stellate cells (HSCs) reduces liver fibrosis (LF). Fgf15–/– mice develop attenuated LF, but the underlying mechanisms for this protection are unclear.

Diagnostic Performance for Hepatic Artery Occlusion After Liver Transplantation: Computed Tomography Angiography Versus Contrast‐Enhanced Ultrasound

Jin Sil Kim, Kyoung Won Kim, Jeongjin Lee, Heon‐Ju Kwon, Jae Hyun Kwon, Gi Won Song, Sung Gyu Lee – 17 June 2019 – The purpose of this study was to compare the diagnostic performance of computed tomography angiography (CTA) and contrast‐enhanced ultrasound (CEUS) when used to diagnose significant hepatic artery occlusion (HAO) in patients that was suspected on Doppler ultrasound (US). Among 3465 adult liver transplantations (LTs) performed between January 2010 and February 2018, 329 recipients were suspected of having HAO by Doppler US.

LiverLearning®: Clinical Hepatology Update Conference 2019

** VIEW ONLY CONTENT . The Clinical Hepatology Update 2019 enduring course will be available soon. It will be available under the "On-Demand Accredited Activities". ** The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.

Depletion of TRRAP Induces p53‐Independent Senescence in Liver Cancer by Down‐Regulating Mitotic Genes

Suet‐Yan Kwan, Ankur Sheel, Chun‐Qing Song, Xiao‐Ou Zhang, Tingting Jiang, Hien Dang, Yueying Cao, Deniz M. Ozata, Haiwei Mou, Hao Yin, Zhiping Weng, Xin Wei Wang, Wen Xue – 12 June 2019 – Hepatocellular carcinoma (HCC) is an aggressive subtype of liver cancer with few effective treatments, and the underlying mechanisms that drive HCC pathogenesis remain poorly characterized. Identifying genes and pathways essential for HCC cell growth will aid the development of new targeted therapies for HCC.

Does Donor Allograft Microsteatosis Matter? Comparison of Outcomes in Liver Transplantation With a Propensity‐Matched Cohort

Kristopher P. Croome, David D. Lee, Sarah Croome, Raouf E. Nakhleh, Peter Abader Sedki Senada, David Livingston, Maria Yataco, C. Burcin Taner – 12 June 2019 – It has been suggested that microsteatosis does not negatively impact graft survival following liver transplantation (LT). The present study represents the largest series on donor livers with significant microsteatosis and investigates the impact of microsteatosis on perioperative factors such as postreperfusion syndrome (PRS), early allograft dysfunction (EAD), and postoperative renal dysfunction.

Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting Antivirals

George N. Ioannou, Pamela K. Green, Kristin Berry, Solomon A. Graf – 11 June 2019 – It is unclear whether eradication of hepatitis C virus (HCV) leads to a reduction in the risk of hematologic malignancies. We aimed to determine the impact of sustained virologic response (SVR) induced by either direct‐acting antivirals (DAAs) or interferon (IFN) on the risk of hematologic malignancies.

Subscribe to